Claims
- 1. A method of detecting a metastatic colorectal cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26.
- 2. The method of claim 1, wherein the biological sample comprises isolated nucleic acids.
- 3. The method of claim 1, wherein the polynucleotide is labeled.
- 4. The method of claim 1, wherein the polynucleotide is immobilized on a solid surface.
- 5. An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-26.
- 6. An expression vector comprising the nucleic acid of claim 5.
- 7. A host cell comprising the expression vector of claim 6.
- 8. An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-26.
- 9. An antibody that specifically binds a polypeptide of claim 8.
- 10. The antibody of claim 10, which is an antibody fragment.
- 11. The antibody of claim 10, which is a humanized antibody
- 12. A method of detecting a metastatic colorectal cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody of claim 9.
- 13. The method of claim 12, wherein the antibody is labeled.
- 14. A method of detecting antibodies specific to metastatic colorectal cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprises a sequence from Tables 1-26.
- 15. A method for identifying a compound that modulates a metastatic colorectal cancer-associated polypeptide, the method comprising the steps of:
(i) contacting the compound with a metastatic colorectal cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26.; and (ii) determining the functional effect of the compound upon the polypeptide.
- 16. The method of claim 15, wherein the functional effect is determined by measuring ligand binding to the polypeptide.
- 17. A method of inhibiting proliferation of a metastatic colorectal cancer-associated cell to treat colorectal cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound that modulates a polypeptide encoded by a sequence as shown in Tables 1-26.
- 18. A drug screening assay comprising the steps of
(i) administering a test compound to a mammal having colorectal cancer or a cell isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26. In a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of colorectal cancer.
- 19. A pharmaceutical composition for treating a mammal having colorectal cancer, the composition comprising a compound identified by the assay of claim 18 and a physiologically acceptable excipient.
- 20. A method of detecting a metastatic colorectal cancer-associated polypeptide in a cell from a patient, the method comprising contacting a biological sample from the patient with a antibody that that specifically binds a polypeptide encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-26.
- 21. The method of claim 21, wherein the antibody is labeled.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] The present application is related to U.S. S No. 60/272,206, filed Feb. 27, 2001, U.S. S No. 60/281,149, filed Apr. 2, 2001, and U.S. S No. 60/284,555, filed Apr. 17, 2001, all of which are herein incorporated by referenced in their entirety.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60284555 |
Apr 2001 |
US |
|
60281149 |
Apr 2001 |
US |
|
60272206 |
Feb 2001 |
US |